Drugs / HRS-5817
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07238647 | Jan 2026 → Jan 2027 expected | obesity disorder | Atridia Pty Ltd. | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06934408 | May 2025 → Apr 2027 expected | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06934408 ↗ |
| Route | Subcutaneous | “HRS-5817 injection administered subcutaneously (SC).” NCT06934408 ↗ |